耐多药结核病防治规划管理研究现状

结核病与肺部健康杂志 ›› 2012, Vol. 1 ›› Issue (1): 70-73.

耐多药结核病防治规划管理研究现状

陈明亭,陈诚

102206 北京,中国疾病预防控制中心结核病预防控制中心

收稿日期:2012-07-16 出版日期:2012-07-20 发布日期:2012-07-20
通信作者: 陈明亭,Email: chenmt@chinatb.org

The research status of programmatic treatment and management of MDR-TB

CHEN Ming-ting,CHEN Cheng

National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China

Received:2012-07-16 Online:2012-07-20 Published:2012-07-20
Contact: CHEN Ming-ting, Email: chenmt@chinatb.org

摘要/Abstract

摘要： 中国的耐多药结核病疫情十分严重,中国耐多药结核病负担居世界第一位,耐多药结核病防治工作刻不容缓。作者对世界卫生组织有关耐多药结核病的规划管理措施,以及中国对耐多药结核病规划管理有关措施,中国对非耐药结核病规划管理有关措施进行了综述,提出了自己的意见和建议,对于今后一段时间加强耐多药结核病防治规划管理工作具有十分重要的指导意义。

Abstract: The epidemic of Multi-drug resistance Tuberculosis (MDR-TB) is very serious in China. Globally China is the largest country of MDR-TB. The control and prevention of MDR-TB admits of no delay. The author reviewed the measures of programmatic treatment and management of MDR-TB issued by World Health Organization and control measures of non-MDR-TB in China, and put forward their views and recommendations for strengthening the management of MDR-TB which are of great significance in guiding the MDR-TB control and prevention in the coming period of time.

陈明亭,陈诚. 耐多药结核病防治规划管理研究现状[J]. 结核病与肺部健康杂志, 2012, 1(1): 70-73.

CHEN Ming-ting,CHEN Cheng. The research status of programmatic treatment and management of MDR-TB[J]. Journal of Tuberculosis and Lung Health, 2012, 1(1): 70-73.